UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Antimicrobial agents and chemotherapy, 2022-01, Vol.66 (1), p.e0164321-e0164321

2022

Volltextzugriff (PDF)

Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study

Antiviral therapy, 2022-04, Vol.27 (2)

2022

Volltextzugriff (PDF)

Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia

Journal of translational medicine, 2019-11, Vol.17 (1), p.365-365, Article 365

2019

Volltextzugriff (PDF)

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

The Lancet infectious diseases, 2019-03, Vol.19 (3), p.253-264

2019

Volltextzugriff (PDF)

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Journal of acquired immune deficiency syndromes (1999), 2020-03, Vol.83 (3), p.310-318

2020

Volltextzugriff (PDF)

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

AIDS (London), 2022-01, Vol.36 (1), p.39-48

2022

Volltextzugriff (PDF)

Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies

Journal of acquired immune deficiency syndromes (1999), 2023-11, Vol.94 (3), p.e9-e12

2023

Volltextzugriff (PDF)

Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis

Journal of acquired immune deficiency syndromes (1999), 2020-05, Vol.84 (1), p.60-65

2020

Volltextzugriff (PDF)

The Bacillus subtilis cell division protein FtsL localizes to sites of septation and interacts with DivIC

Molecular microbiology, 2000-05, Vol.36 (4), p.846-855

2000

Volltextzugriff (PDF)

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

HIV research & clinical practice, 2021-12, Vol.23 (1), p.9-14

2021

Volltextzugriff (PDF)

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

Viruses, 2024-03, Vol.16 (3), p.405

2024

Volltextzugriff (PDF)

Analysis of the essential cell division gene ftsL of Bacillus subtilis by mutagenesis and heterologous complementation

Journal of bacteriology, 2000-10, Vol.182 (19), p.5572-5579

2000

Volltextzugriff (PDF)

EFICÁCIA DURADOURA DE DOLUTEGRAVIR MAIS LAMIVUDINA NO TRATAMENTO ANTIRRETROVIRAL DE ADULTOS NAÏVE COM INFECÇÃO PELO HIV-1: RESULTADOS DE 144 SEMANAS DOS ESTUDOS GEMINI EM PARTICIPANTES DE CENTROS LATINO-AMERICANOS

The Brazilian journal of infectious diseases, 2022-01, Vol.26, p.102125, Article 102125

2022

Volltextzugriff (PDF)

NÃO INFERIORIDADE DE EFICÁCIA DE DOLUTEGRAVIR (DTG) MAIS LAMIVUDIDINA (3 TC) VERSUS DTG MAIS DOSE FIXA COMBINADA DE TENOFOVIR/EMTRICITABINA (TDF/FTC) EM ADULTOS VIRGENS DE TRATAMENTO ANTIRRETROVIRAL QUE VIVEM COM HIV‐1: RESULTADOS DE 48 SEMANAS DOS ESTU

The Brazilian journal of infectious diseases, 2018-12, Vol.22, p.56-57

2018

Volltextzugriff (PDF)

Novel Inhibitors of Bacterial Cytokinesis Identified by a Cell-based Antibiotic Screening Assay

The Journal of biological chemistry, 2005-12, Vol.280 (48), p.39709-39715

2005

Volltextzugriff (PDF)

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S541-S542

2020

Volltextzugriff (PDF)

Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"

Antimicrobial agents and chemotherapy, 2023-02, Vol.67 (3), p.e0032622-e0032622

2023

Volltextzugriff (PDF)

Characterization of the parB-Like yyaA Gene of Bacillus subtilis

Journal of Bacteriology, 2002-02, Vol.184 (4), p.1102-1111

2002

Volltextzugriff (PDF)

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens

The open AIDS journal, 2015, Vol.9 (1), p.38-44

2015

Volltextzugriff (PDF)

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC) PARA TERAPIA ANTIRETROVIRAL DE ADULTOS COM INFECÇÃO POR HIV‐1 SEM TRATAMENTO PRÉVIO ‐ RESULTADO DE 3 ANOS DOS ESTUDOS GEMINI

The Brazilian journal of infectious diseases, 2021-01, Vol.25, p.101259

2021

Volltextzugriff (PDF)

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC) PARA TERAPIA ANTIRETROVIRAL DE ADULTOS COM INFECÇÃO POR HIV‐1 SEM TRATAMENTO PRÉVIO ‐ RESULTADO DE 3 ANOS DOS ESTUDOS GEMINI

The Brazilian journal of infectious diseases, 2021-01, Vol.25, p.101259, Article 101259

2021

Volltextzugriff (PDF)

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S67-S68

2019

Volltextzugriff (PDF)

Characterization of the parB-like yyaA gene of Bacilus subtilis

Journal of bacteriology, 2002-02, Vol.184 (4), p.1102

2002

Volltextzugriff (PDF)

Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children

The Pediatric infectious disease journal, 2014-01, Vol.33 (1), p.50-56

2014

Volltextzugriff (PDF)

EFICÁCIA SUPERIOR DE DOLUTEGRAVIR (DTG) MAIS 2 INIBIDORES DA TRANSCRIPTASE REVERSA (ITRNS) COMPARADA COM LOPINAVIR/R MAIS 2 ITRNS NA SEGUNDA LINHA DE TRATAMENTO – DADOS DE 48 SEMANAS DO ESTUDO DAWNING

The Brazilian journal of infectious diseases, 2018-12, Vol.22, p.56-56

2018

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study

Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies

Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis

The Bacillus subtilis cell division protein FtsL localizes to sites of septation and interacts with DivIC

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

Analysis of the essential cell division gene ftsL of Bacillus subtilis by mutagenesis and heterologous complementation

EFICÁCIA DURADOURA DE DOLUTEGRAVIR MAIS LAMIVUDINA NO TRATAMENTO ANTIRRETROVIRAL DE ADULTOS NAÏVE COM INFECÇÃO PELO HIV-1: RESULTADOS DE 144 SEMANAS DOS ESTUDOS GEMINI EM PARTICIPANTES DE CENTROS LATINO-AMERICANOS

NÃO INFERIORIDADE DE EFICÁCIA DE DOLUTEGRAVIR (DTG) MAIS LAMIVUDIDINA (3 TC) VERSUS DTG MAIS DOSE FIXA COMBINADA DE TENOFOVIR/EMTRICITABINA (TDF/FTC) EM ADULTOS VIRGENS DE TRATAMENTO ANTIRRETROVIRAL QUE VIVEM COM HIV‐1: RESULTADOS DE 48 SEMANAS DOS ESTU

Novel Inhibitors of Bacterial Cytokinesis Identified by a Cell-based Antibiotic Screening Assay

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials

Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study"

Characterization of the parB-Like yyaA Gene of Bacillus subtilis

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC) PARA TERAPIA ANTIRETROVIRAL DE ADULTOS COM INFECÇÃO POR HIV‐1 SEM TRATAMENTO PRÉVIO ‐ RESULTADO DE 3 ANOS DOS ESTUDOS GEMINI

EFICÁCIA DURADOURA DE DOLUTEGRAVIR (DTG) E LAMIVUDINA (3 TC) PARA TERAPIA ANTIRETROVIRAL DE ADULTOS COM INFECÇÃO POR HIV‐1 SEM TRATAMENTO PRÉVIO ‐ RESULTADO DE 3 ANOS DOS ESTUDOS GEMINI

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies

Characterization of the parB-like yyaA gene of Bacilus subtilis

Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children

EFICÁCIA SUPERIOR DE DOLUTEGRAVIR (DTG) MAIS 2 INIBIDORES DA TRANSCRIPTASE REVERSA (ITRNS) COMPARADA COM LOPINAVIR/R MAIS 2 ITRNS NA SEGUNDA LINHA DE TRATAMENTO – DADOS DE 48 SEMANAS DO ESTUDO DAWNING

Suchergebnisse filtern